BARCLAYS PLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 116 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q2 2024$51
-63.3%
51,376
-45.3%
0.00%
Q1 2024$139
-30.5%
93,927
-48.8%
0.00%
Q4 2023$200
+614.3%
183,292
+663.8%
0.00%
Q3 2023$28
-22.2%
23,996
-7.4%
0.00%
Q2 2023$36
+71.4%
25,905
+87.3%
0.00%
Q1 2023$21
-36.4%
13,830
-50.8%
0.00%
Q4 2022$33
-99.6%
28,109
+268.1%
0.00%
Q3 2022$9,000
-71.0%
7,637
-62.5%
0.00%
Q1 2022$31,00020,3600.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$52,403,2283.69%
Raffles Associates 1,536,946$2,305,4193.14%
Defender Capital, LLC. 5,136,085$7,704,1282.69%
Prescott General Partners LLC 1,851,851$2,777,7770.22%
DAFNA Capital Management LLC 140,000$210,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$67,5000.05%
CTC Capital Management, LLC 14,100$21,1500.04%
Diametric Capital, LP 50,875$76,3130.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$1,172,6490.03%
One68 Global Capital, LLC 13,377$20,0660.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders